Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Tumor infarction by targeting tissue factor to tumor vasculature.

Thorpe PE, Ran S.

Cancer J. 2000 May;6 Suppl 3:S237-44. Review. No abstract available.

PMID:
10874493
2.

Therapeutic targeting of the tumor vasculature.

Tozer GM, Bicknell R.

Semin Radiat Oncol. 2004 Jul;14(3):222-32. Review.

PMID:
15254865
3.

Drug targeting to specific vascular sites.

Ruoslahti E.

Drug Discov Today. 2002 Nov 15;7(22):1138-43. Review.

PMID:
12546857
4.

Targeting tumor vasculature: reality or a dream?

Satchi-Fainaro R.

J Drug Target. 2002 Nov;10(7):529-33. Review. No abstract available.

PMID:
12683719
5.

Tissue factor and angiogenesis in cancer.

Fernandez PM, Rickles FR.

Curr Opin Hematol. 2002 Sep;9(5):401-6. Review.

PMID:
12172458
6.

Targeting the tumor stroma in cancer therapy.

Anton K, Glod J.

Curr Pharm Biotechnol. 2009 Feb;10(2):185-91. Review.

PMID:
19199950
7.

Targeting small molecules in cancer.

Wanebo HJ, Berz D, Mega A.

Cancer Treat Res. 2007;135:239-55. Review. No abstract available.

PMID:
17953421
8.

Clinical use of therapies targeting tumor vasculature and stroma.

Davis ID, Desai J.

Curr Cancer Drug Targets. 2008 Sep;8(6):498-508. Review.

PMID:
18781896
9.

Tumor vascular infarction: prospects and challenges.

Jahanban-Esfahlan R, Seidi K, Zarghami N.

Int J Hematol. 2017 Mar;105(3):244-256. doi: 10.1007/s12185-016-2171-3. Epub 2017 Jan 2. Review.

PMID:
28044258
10.

Antiangiogenic tumor therapy.

Davis DW, McConkey DJ, Zhang W, Herbst RS.

Biotechniques. 2003 May;34(5):1048-50, 1052, 1054 passim. Review. No abstract available.

PMID:
12765031
11.

III. Angiogenesis: complexity of tumor vasculature and microenvironment.

Furuya M, Yonemitsu Y, Aoki I.

Curr Pharm Des. 2009;15(16):1854-67. Review.

PMID:
19519428
12.

Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.

ten Hagen TL, Seynhaeve AL, Eggermont AM.

Immunol Rev. 2008 Apr;222:299-315. doi: 10.1111/j.1600-065X.2008.00619.x. Review.

PMID:
18364010
13.

Targeting tumor vasculature with homing peptides from phage display.

Ruoslahti E.

Semin Cancer Biol. 2000 Dec;10(6):435-42. Review.

PMID:
11170865
14.

Angiogenesis inhibitors. Drug selectivity and target specificity.

Kesisis G, Broxterman H, Giaccone G.

Curr Pharm Des. 2007;13(27):2795-809. Review.

PMID:
17897024
15.

Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging.

Li WW.

Acad Radiol. 2000 Oct;7(10):800-11. Review. No abstract available.

PMID:
11048878
16.

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Jain RK.

Nat Med. 2001 Sep;7(9):987-9. Review. No abstract available.

PMID:
11533692
17.

Optical imaging and tumor angiogenesis.

Lin PC.

J Cell Biochem. 2003 Oct 15;90(3):484-91. Review.

PMID:
14523982
18.
19.

Two-domain vascular disruptive agents in cancer therapy.

Szala S.

Curr Cancer Drug Targets. 2004 Sep;4(6):501-9. Review.

PMID:
15379635
20.

Angiogenesis: a "common denominator" of disease?

Piascik P.

J Am Pharm Assoc (Wash). 2000 Jul-Aug;40(4):564-5. Review. No abstract available.

PMID:
10932469

Supplemental Content

Support Center